| # | Filing Date | Period End Date | Type | Report Link | 
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announ...
																	
																	
																	
																	
																	
																	CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical researchCompanies...
																	
																	In accordance with Listing Rule 5810(c)(3)(A) of the Nasdaq Listing Rules, the Company has a period of 180 calendar days from t...